Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 3/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.48 |
| ▸ | PAK1 | Q13153 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | KRAS | P01116 | 1/20 | 0.44 |
| ▸ | RAF1 | P04049 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | ARAF | P10398 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | FECH | P22830 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL298907 | 0.95 | BRAF (0.54) | BRAFALKCYP2C19PAK1CYP2C9 | |
| SCHEMBL298112 | 0.86 | BRAF (0.56) | BRAFCYP2C19CYP2C9CYP3A4RIPK2 | |
| SCHEMBL298434 | 0.84 | PAK1 (0.56) | ALKPAK1 | |
| SCHEMBL416393 | 0.84 | CDK8 (0.51) | ALKPAK1 | |
| SCHEMBL299032 | 0.83 | BRAF (0.61) | BRAFCYP2C19PAK1CYP2C9CYP3A4 | |
| SCHEMBL19565631 | 0.83 | BRAF (0.61) | BRAFCYP2C19CYP2C9CYP3A4RIPK2 | |
| SCHEMBL299488 | 0.82 | PAK1 (0.54) | ALKPAK1 | |
| SCHEMBL298470 | 0.82 | PIK3CA (0.50) | ALKCYP2C19PAK1CYP2C9CYP3A4 | |
| SCHEMBL297385 | 0.82 | CYP3A4 (0.51) | ALKPAK1CYP2C9CYP3A4EGFR | |
| SCHEMBL298148 | 0.82 | EGFR (0.57) | BRAFALKPAK1EGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| EP-2427433-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | Plexxikon, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | BRAF, RAF1, ARAF | BRAF 1/4885ALK 679/4885CYP2C19 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.